SG11201906891RA - Methods for the administration of certain vmat2 inhibitors - Google Patents
Methods for the administration of certain vmat2 inhibitorsInfo
- Publication number
- SG11201906891RA SG11201906891RA SG11201906891RA SG11201906891RA SG11201906891RA SG 11201906891R A SG11201906891R A SG 11201906891RA SG 11201906891R A SG11201906891R A SG 11201906891RA SG 11201906891R A SG11201906891R A SG 11201906891RA SG 11201906891R A SG11201906891R A SG 11201906891RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- methods
- administration
- english
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 abstract 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 abstract 1
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229950006411 valbenazine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451605P | 2017-01-27 | 2017-01-27 | |
| PCT/US2017/055980 WO2018140096A1 (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906891RA true SG11201906891RA (en) | 2019-08-27 |
Family
ID=62978647
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906891RA SG11201906891RA (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
| SG11201906883SA SG11201906883SA (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
| SG11201906885TA SG11201906885TA (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906883SA SG11201906883SA (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
| SG11201906885TA SG11201906885TA (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US10874648B2 (ru) |
| JP (11) | JP7107950B2 (ru) |
| KR (10) | KR20190108149A (ru) |
| CN (6) | CN111655034A (ru) |
| AU (7) | AU2017395700B2 (ru) |
| CA (5) | CA3051832A1 (ru) |
| EA (5) | EA201991782A1 (ru) |
| MX (6) | MX2019008868A (ru) |
| MY (2) | MY191077A (ru) |
| PH (5) | PH12019501734A1 (ru) |
| SG (3) | SG11201906891RA (ru) |
| WO (5) | WO2018140093A1 (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180075591A (ko) | 2015-10-30 | 2018-07-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 발베나진 염 및 그의 다형체 |
| HUE059065T2 (hu) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására |
| CA3051832A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組 |
| US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
| WO2019129100A1 (zh) | 2017-12-26 | 2019-07-04 | 苏州科睿思制药有限公司 | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 |
| JOP20200336A1 (ar) * | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| CN114340624A (zh) * | 2019-05-09 | 2022-04-12 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EP4362944A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| CA3221728A1 (en) | 2021-06-30 | 2023-01-05 | Grace S. LIANG | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
| WO2023023026A1 (en) * | 2021-08-16 | 2023-02-23 | Foresee Pharmaceuticals Co., Ltd. | Polymer depot compositions for sustained release delivery of vmat2 inhibitors |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| WO2023039187A1 (en) * | 2021-09-10 | 2023-03-16 | ATAI Life Sciences AG | Ibogaine combination treatment |
| WO2023076568A1 (en) * | 2021-10-29 | 2023-05-04 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
| WO2023172849A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1068938A (en) | 1910-11-07 | 1913-07-29 | Gustav F Schulze | Vehicle-apron. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5283918A (en) | 1976-01-01 | 1977-07-13 | Wellcome Found | Pharmaceutical composition |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5777697A (en) | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| JPS57209225A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| JPS6028987A (ja) | 1983-07-28 | 1985-02-14 | Chugai Pharmaceut Co Ltd | 新規ジゴキシン誘導体 |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| AU1321900A (en) | 1998-10-23 | 2000-05-15 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| CA2487732C (en) | 2002-05-28 | 2013-10-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| WO2004026258A2 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease |
| US7230097B2 (en) | 2003-03-10 | 2007-06-12 | Lupin Ltd. | Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid |
| GB0307259D0 (en) | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| AR049200A1 (es) | 2004-06-04 | 2006-07-05 | Genentech Inc | Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20 |
| CA2582022C (en) | 2004-09-30 | 2021-05-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
| EP1804807B1 (en) | 2004-10-28 | 2008-12-03 | Wyeth a Corporation of the State of Delaware | Coadministration of tigecycline and digoxin |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| ATE415968T1 (de) | 2005-08-06 | 2008-12-15 | Cambridge Lab Ireland Ltd | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen |
| US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| CA2668689C (en) * | 2006-11-08 | 2015-12-29 | Neurocrine Biosciences Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| GB0721669D0 (en) | 2007-11-02 | 2007-12-12 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US8158620B2 (en) | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20100096319A1 (en) | 2008-10-17 | 2010-04-22 | General Electric Company | Separator assembly |
| SI2417267T1 (sl) | 2009-04-06 | 2017-02-28 | Vanda Pharmaceuticals Inc. | Postopek zdravljenja na podlagi polimorfizmov gena KCNQ1 |
| EP2464340A2 (en) | 2009-08-12 | 2012-06-20 | Valeant International (Barbados) SRL | Pharmaceutical compositions with tetrabenazine |
| EP3351247A1 (en) * | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012153341A1 (en) | 2011-05-12 | 2012-11-15 | Arch Pharmalabs Limited | A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof |
| IN2015DN01662A (ru) | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
| CA2893542C (en) * | 2012-12-18 | 2022-07-19 | Vanda Pharmaceuticals Inc. | Use of tasimelteon in the treatment of circadian rhythm disorders |
| BR112015017878A2 (pt) * | 2013-01-31 | 2017-07-11 | Auspex Pharmaceuticals Inc | composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2 |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EA201691512A1 (ru) | 2014-01-27 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 |
| CN113413385A (zh) | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| IL248745B (en) | 2014-05-06 | 2022-07-01 | Neurocrine Biosciences | (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza |
| ES2960717T3 (es) | 2015-02-06 | 2024-03-06 | Neurocrine Biosciences Inc | [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo |
| PL3265085T3 (pl) | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| MX2017017015A (es) | 2015-06-23 | 2018-02-26 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
| KR20180075591A (ko) | 2015-10-30 | 2018-07-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 발베나진 염 및 그의 다형체 |
| HUE059065T2 (hu) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására |
| JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| CA3051832A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| AU2018241940B2 (en) | 2017-04-01 | 2023-09-28 | Adeptio Pharmaceuticals Limited | Dihydrotetrabenazine for use in the treatment a movement disorder |
| CA3057543A1 (en) | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| US20200179352A1 (en) | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| JP2020520380A (ja) * | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組 |
| US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
| WO2019104141A1 (en) | 2017-11-22 | 2019-05-31 | Teva Pharmaceuticals Usa, Inc. | Solid state form of valbenazine |
| SG11202011544UA (en) | 2018-06-14 | 2020-12-30 | Neurocrine Biosciences Inc | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| CN114340624A (zh) | 2019-05-09 | 2022-04-12 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
-
2017
- 2017-10-10 CA CA3051832A patent/CA3051832A1/en active Granted
- 2017-10-10 KR KR1020197024657A patent/KR20190108149A/ko active Application Filing
- 2017-10-10 KR KR1020237007871A patent/KR20230038601A/ko not_active Application Discontinuation
- 2017-10-10 WO PCT/US2017/055907 patent/WO2018140093A1/en active Application Filing
- 2017-10-10 CA CA3051830A patent/CA3051830A1/en active Pending
- 2017-10-10 KR KR1020197024655A patent/KR20190108147A/ko active Application Filing
- 2017-10-10 WO PCT/US2017/055980 patent/WO2018140096A1/en active Application Filing
- 2017-10-10 KR KR1020237041673A patent/KR20230169457A/ko not_active Application Discontinuation
- 2017-10-10 MY MYPI2019004293A patent/MY191077A/en unknown
- 2017-10-10 CN CN201780097535.7A patent/CN111655034A/zh active Pending
- 2017-10-10 JP JP2019540650A patent/JP7107950B2/ja active Active
- 2017-10-10 CA CA3051834A patent/CA3051834A1/en active Granted
- 2017-10-10 US US16/481,033 patent/US10874648B2/en active Active
- 2017-10-10 MX MX2019008868A patent/MX2019008868A/es unknown
- 2017-10-10 CN CN201780088736.0A patent/CN110709071A/zh active Pending
- 2017-10-10 JP JP2020520311A patent/JP7090151B2/ja active Active
- 2017-10-10 JP JP2019540570A patent/JP7199361B2/ja active Active
- 2017-10-10 KR KR1020207012774A patent/KR20200066662A/ko not_active Application Discontinuation
- 2017-10-10 MX MX2020003462A patent/MX2020003462A/es unknown
- 2017-10-10 US US16/481,037 patent/US20200093808A1/en not_active Abandoned
- 2017-10-10 MY MYPI2019004292A patent/MY195934A/en unknown
- 2017-10-10 AU AU2017395700A patent/AU2017395700B2/en active Active
- 2017-10-10 AU AU2017395701A patent/AU2017395701B2/en active Active
- 2017-10-10 EA EA201991782A patent/EA201991782A1/ru unknown
- 2017-10-10 CA CA3051829A patent/CA3051829A1/en active Pending
- 2017-10-10 EA EA201991780A patent/EA201991780A1/ru unknown
- 2017-10-10 KR KR1020237041797A patent/KR20230170135A/ko not_active Application Discontinuation
- 2017-10-10 AU AU2017395702A patent/AU2017395702B2/en active Active
- 2017-10-10 AU AU2017395703A patent/AU2017395703B2/en active Active
- 2017-10-10 JP JP2019540568A patent/JP7199360B2/ja active Active
- 2017-10-10 WO PCT/US2017/055931 patent/WO2018140094A1/en active Application Filing
- 2017-10-10 SG SG11201906891RA patent/SG11201906891RA/en unknown
- 2017-10-10 US US16/481,029 patent/US20190381016A1/en not_active Abandoned
- 2017-10-10 CN CN202310682815.1A patent/CN116712434A/zh active Pending
- 2017-10-10 JP JP2019540557A patent/JP7199359B2/ja active Active
- 2017-10-10 EA EA202090676A patent/EA202090676A1/ru unknown
- 2017-10-10 KR KR1020197024656A patent/KR20190108148A/ko not_active IP Right Cessation
- 2017-10-10 KR KR1020207030652A patent/KR20200126430A/ko active Application Filing
- 2017-10-10 WO PCT/US2017/055965 patent/WO2018140095A2/en active Application Filing
- 2017-10-10 SG SG11201906883SA patent/SG11201906883SA/en unknown
- 2017-10-10 KR KR1020237041798A patent/KR20230170136A/ko not_active Application Discontinuation
- 2017-10-10 AU AU2017395704A patent/AU2017395704B8/en active Active
- 2017-10-10 MX MX2019008855A patent/MX2019008855A/es unknown
- 2017-10-10 EA EA201991784A patent/EA201991784A1/ru unknown
- 2017-10-10 SG SG11201906885TA patent/SG11201906885TA/en unknown
- 2017-10-10 CN CN201780088897.XA patent/CN110769826A/zh active Pending
- 2017-10-10 KR KR1020197024654A patent/KR20190108146A/ko not_active Application Discontinuation
- 2017-10-10 MX MX2019008853A patent/MX2019008853A/es unknown
- 2017-10-10 CN CN201780088730.3A patent/CN110740731A/zh active Pending
- 2017-10-10 CA CA3078719A patent/CA3078719A1/en active Pending
- 2017-10-10 CN CN201780088766.1A patent/CN110740732A/zh active Pending
- 2017-10-10 WO PCT/US2017/055877 patent/WO2018140092A1/en active Application Filing
- 2017-10-10 MX MX2019008854A patent/MX2019008854A/es unknown
- 2017-10-10 EA EA201991786A patent/EA201991786A1/ru unknown
-
2019
- 2019-07-25 MX MX2022007141A patent/MX2022007141A/es unknown
- 2019-07-26 PH PH12019501734A patent/PH12019501734A1/en unknown
- 2019-07-26 PH PH12019501732A patent/PH12019501732A1/en unknown
- 2019-07-26 PH PH12019501740A patent/PH12019501740A1/en unknown
- 2019-07-26 PH PH12019501744A patent/PH12019501744A1/en unknown
-
2020
- 2020-04-08 PH PH12020550238A patent/PH12020550238A1/en unknown
- 2020-05-08 US US16/870,423 patent/US10952997B2/en active Active
- 2020-05-08 US US16/870,706 patent/US10857137B2/en active Active
- 2020-05-08 US US16/870,572 patent/US11040029B2/en active Active
- 2020-10-17 US US17/073,304 patent/US10912771B1/en active Active
- 2020-10-26 US US17/080,343 patent/US11439629B2/en active Active
- 2020-12-17 US US17/125,190 patent/US20210169862A1/en not_active Abandoned
-
2022
- 2022-01-24 JP JP2022008580A patent/JP2022040408A/ja not_active Withdrawn
- 2022-05-12 AU AU2022203201A patent/AU2022203201B2/en active Active
- 2022-05-17 AU AU2022203327A patent/AU2022203327A1/en active Pending
- 2022-07-14 JP JP2022113075A patent/JP2022137219A/ja active Pending
- 2022-10-04 JP JP2022160177A patent/JP2022174343A/ja active Pending
- 2022-10-05 JP JP2022160831A patent/JP2022174344A/ja active Pending
- 2022-10-05 JP JP2022160833A patent/JP2022174345A/ja active Pending
-
2023
- 2023-09-15 JP JP2023149999A patent/JP2023161033A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201408261UA (en) | Syringe | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906238TA (en) | Split sector level sweep using beamforming refinement frames | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases |